Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) Tax Provisions (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Tax Provisions for 5 consecutive years, with $760000.0 as the latest value for Q2 2025.

  • On a quarterly basis, Tax Provisions rose 744.44% to $760000.0 in Q2 2025 year-over-year; TTM through Nov 2025 was $760000.0, a 181.48% increase, with the full-year FY2025 number at $760000.0, up 181.48% from a year prior.
  • Tax Provisions was $760000.0 for Q2 2025 at Nurix Therapeutics, up from $8000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $760000.0 in Q2 2025 to a low of -$123000.0 in Q3 2021.
  • A 3-year average of $126444.4 and a median of $82000.0 in 2024 define the central range for Tax Provisions.
  • Biggest YoY gain for Tax Provisions was 3200.0% in 2021; the steepest drop was 545.45% in 2021.
  • Nurix Therapeutics' Tax Provisions stood at $31000.0 in 2021, then crashed by 74.19% to $8000.0 in 2024, then surged by 9400.0% to $760000.0 in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Tax Provisions are $760000.0 (Q2 2025), $8000.0 (Q4 2024), and $82000.0 (Q3 2024).